Research programme: Neurological disorders therapeutics - MicroQuin Therapeutics
Latest Information Update: 12 Sep 2024
At a glance
- Originator MicroQuin
- Class Antidementias; Antiparkinsonians; Neuroprotectants
- Mechanism of Action Bcl-X protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Parkinson's disease; Traumatic brain injuries
- Research Alzheimer's disease
Most Recent Events
- 10 Sep 2024 Early research in Alzheimer's disease in USA (unspecified route) prior to September 2024 (MicroQuin pipeline, September 2024)
- 10 Sep 2024 Preclinical trials in Traumatic brain injuries in USA (unspecified route) prior to September 2024 (MicroQuin pipeline, September 2024)
- 03 Sep 2021 Preclinical trials in Parkinson's disease in USA (unspecified route)